(Q34065241)

30 July 2017

Efficacy of a high and accelerated dose of hepatitis B vaccine in alcoholic patients: a randomized clinical trial (English)

1 reference

30 July 2017

0 references

1 reference

1 reference

Rosman AS

1

1 reference

30 July 2017

Basu P

series ordinal

2

1 reference

30 July 2017

Galvin K

series ordinal

3

1 reference

30 July 2017

Lieber CS

series ordinal

4

1 reference

30 July 2017

language of work or name

English

0 references

publication date

1 September 1997

1 reference

American Journal of Medicine

30 July 2017

1 reference

30 July 2017

103

1 reference

30 July 2017

217-222

1 reference

30 July 2017

3

1 reference

Human immunodeficiency virus and hepatitis B virus infections in a New York City alcoholic population

30 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900132-0

Prevalence of markers of hepatitis viruses in out-patient alcoholics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900132-0

Intravenous drug abuse--the major route of hepatitis C virus transmission among alcohol-dependent individuals?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900132-0

A reappraisal of hepatitis B virus vaccination strategies using cost-effectiveness analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900132-0

Hepatitis B vaccination in chronic alcoholics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900132-0

Hepatitis B vaccination. Response of alcoholic with and without liver injury

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900132-0

Hepatitis B vaccination in alcoholics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900132-0

Secondary immune response to hepatitis B virus vaccine in alcoholics.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900132-0

Hepatitis B vaccine: immune responses in haemodialysis patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900132-0

Hepatitis B vaccines in patients with chronic renal failure before dialysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900132-0

Immunogenicity of a yeast-derived hepatitis B vaccine in hemodialysis patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900132-0

Hepatitis B vaccination: how long does protection last?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900132-0

Immune response to hepatitis B vaccine in staff and patients in renal dialysis units

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900132-0

Utility of carbohydrate-deficient transferrin as a marker of relapse in alcoholic patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900132-0

Factors influencing the immune response to hepatitis B vaccine, booster dose guidelines, and vaccine protocol recommendations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900132-0

Hepatitis B immunization strategies: expanding the target

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900132-0

The changing epidemiology of hepatitis B in the United States. Need for alternative vaccination strategies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900132-0

Antibody to human immunodeficiency virus (HIV) and suboptimal response to hepatitis B vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900132-0

Nonresponsiveness to hepatitis B vaccine in health care workers. Results of revaccination and genetic typings

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900132-0

Immune suppression gene on HLA-Bw54-DR4-DRw53 haplotype controls nonresponsiveness in humans to hepatitis B surface antigen via CD8+ suppressor T cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900132-0

Genetic prediction of nonresponse to hepatitis B vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900132-0

HLA linked immune response to S and pre-S2 gene products in hepatitis B vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900132-0

Long-term management of the liver transplant recipient

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900132-0

Response to HBV vaccination in patients with severe liver disease. Absence of an HLA effect

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900132-0

Controlled trial of thymopentin in hemodialysis patients who fail to respond to hepatitis B vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900132-0

Low-dose interleukin-2 induces systemic immune responses against HBsAg in immunodeficient non-responders to hepatitis B vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900132-0

Randomized comparative trial of interferon-alpha versus placebo in hepatitis B vaccine non-responders and hyporesponders

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900132-0

Immunogenicity of the recombinant GenHevac B Pasteur vaccine against hepatitis B in chronic uremic patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900132-0

Safety and efficacy of a recombinant yeast-derived pre-S2 + S-containing hepatitis B vaccine (TGP-943): phase 1, 2 and 3 clinical testing

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900132-0

Indications for use of hepatitis B vaccine, based on cost-effectiveness analysis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900132-0

Alcohol, hepatotropic viruses, and hepatocellular carcinoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900132-0

10.1016/S0002-9343(97)00132-0

7 January 2021

Identifiers

DOI

1 reference

30 July 2017

1 reference